For further information contact
Biologics are some of the most profitable and widely prescribed medicines. Biosimilars are similar versions of biologic medicines, and offer considerable cost savings to public health systems.
Our experts will discuss the evolving landscape facing both manufacturers of biologics and biosimilars. In particular, they will consider the potential for biosimilar products to enter the valuable medicines market during the next few years as a result of many biologic products coming off patent. They will also look at the opportunities for innovator biologics, including how the presence of biosimilars may drive innovators to break new ground.
This webinar will focus on innovative patent strategies in Europe, including pre-emptive measures, leveraging the timeline of proceedings in different European jurisdictions and other novel litigation tools.
Pinsent Masons advises on purchase of Northern Ireland’s first major energy storage project